Browse Technologies
Browse Technologies
Technology Keyword Search
Small Molecule Therapeutics
Search Results
Displaying: 1 - 10 of 18 Results
Compounds that block human cytomegalovirus by targeting the nuclear egress complex
Researchers in Dr. Donald Coen’s lab have identified molecules that inhibit human cytomegalovirus (HCMV) virion egress from the cell, effectively inhibiting HCMV replication. The team is looking to expand on these findings in collaborations that…
DBD
- Grant Zimmermann
Investigators
- Donald Coen
Novel annulation catalysts via direct C-H bond amination
Introducing functionality into unactivated C-H bonds, a ubiquitous group in organic molecules, remains a significant challenge due to the inertness of the substrate. Traditional synthesis strategies involve functional group exchange, an inefficient…
DBD
- Christopher Petty
Investigators
- Theodore Betley
- Elisabeth Hennessy
- Alexandre Mikhailine
- Claudia Kleinlein
- Yuyang Dong
- Yunjung Baek
Polymixin synergistic novobiocin analogs for efficacious and safer treatment of Gram negative infections
The lipopolysaccharide (LPS) containing outer membrane of Gram-negative bacteria prevent penetration of antibiotics, making them ineffective against infections. Polymyxins, including colistin, bind LPS and disrupt the outer membrane and hence are…
DBD
- Vivian Berlin
Investigators
- Daniel Kahne
Stapled peptide that inhibits bacterial transporter
Multidrug-resistant infection has become a worldwide epidemic in recent years especially in hospitals and other community-associated settings, causing great suffering of patients and huge healthcare burden. According to CDC, at least 23,000 people…
DBD
- Vivian Berlin
Investigators
- Martin Karplus
Novel antibiotics against Gram-negative and drug-resistant bacterial pathogens
Dr. Kahne has a pipeline of programs aimed at developing first-in-class antibiotics:Program I: Potentiator of polymixin, increasing its therapeutic index for treatment of drug-resistant infectionsIn vitro: Novel agent potentiates activity of…
DBD
- Vivian Berlin
Investigators
- Daniel Kahne
SIM-PAL: proteome wide identification of small molecule binding sites
Precise target identification for small molecules is an important and essential step in drug development. Despite its importance, there are very few unbiased, proteome-wide approaches aimed at identifying binding partners for small molecules. In…
DBD
- Grant Zimmermann
Investigators
- Christina Woo
Small molecule inhibitors of Zika, dengue and other flaviviruses
Currently, broadly-protective antivirals targeting flaviviruses such as Zika, Dengue and West Nile viruses, are not available. Researchers in the laboratory of Dr. Priscilla Yang have identified a group of small molecules, including a prototype…
DBD
- Vivian Berlin
Investigators
- Priscilla Yang
Targeting spiral ganglion neurons for treatment of hearing loss
Hearing loss makes interactions with the world challenging for over 30 million people in the United States. While cochlear implants and hearing aid devices can ameliorate hearing loss, they often fail to restore the function of spiral ganglion…
DBD
- Irit Ben-Chelouche
Investigators
- Lisa Goodrich
Inhibitors of protein-processivity factor
Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions,…
DBD
- Grant Zimmermann
Investigators
- Donald Coen
- James Hogle
- Harmon Zuccola
- Kristie Bridges
- Carl Elkin
- Scott Lokey
Lead compounds for the treatment of pain
The invention is a novel synthetic pathway to the generation of nonpeptidic ligands for the mu opioid class of G-protein coupled receptors. The system uses stereochemical variation and acyclic geometric stereocontrol to generate diversity among its…
DBD
- Vivian Berlin
Investigators
- Gregory Verdine
- Bryce Harrison
- Tiffany Gierasch
- Zhangjie Shi